November 4, 1998
AMERIPATH ACQUIRES PATHOLOGY PRACTICES

Riviera Beach, FL, November 4, 1998 - AmeriPath, Inc. (Nasdaq: PATH), a physician practice management company focused on anatomic pathology services, continues to build on its regional business models by announcing the acquisition of two anatomic pathology practices located in Florida and Ohio. The practices had combined annual net revenues of $3.4 million for 1997. Terms of the transactions were not disclosed.

Susan R. Baker, Ph.D., M.D., P.A. is AmeriPath's eleventh acquisition in the state of Florida. The hospital based practice employs two physicians who provide inpatient services at North Shore Medical Center ("North Shore"), in Miami, Florida. Dr. Susan Baker serves as a Governing Board Member for North Shore.

Pathology Consultants of Cleveland, Inc. is also hospital based where its four physicians provide anatomic pathology services through inpatient and outpatient operations at Mt. Sinai Medical Center, Cleveland, Ohio. The practice also provides services to two other hospitals in the area.

"The acquisition of these two well established and highly respected practices further exemplify our business strategy to expand AmeriPath's presence in existing markets and to provide for additional economies of scale," said James C. New, President and CEO of AmeriPath, Inc. "We're proud to have them as a part of the AmeriPath team."

AmeriPath, Inc. is the nation's leading physician practice management company focused on providing anatomic pathology services to physicians, hospitals, national clinical laboratories and managed care organizations. The Company presently operates in ten states, employs 226 pathologists who provide medical services through outpatient pathology laboratories, hospital inpatient laboratories and outpatient surgery centers.

.....................................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath's actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursements, dependence upon contracts and pathologists, acquisitions, integration of acquired practices, the market for pathology services, competition, and other factors identified in AmeriPath's filings with the Securities and Exchange Commission.